Collegium Pharmaceutical ... (COLL)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
33.15
-0.64 (-1.89%)
At close: Jan 14, 2025, 3:59 PM
33.18
0.09%
After-hours Jan 14, 2025, 04:00 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
Revenue | 566.77M | 463.93M | 276.87M | 310.02M | 296.70M | 280.41M | 28.48M | 1.71M | n/a | n/a | n/a |
Cost of Revenue | 240.60M | 254.44M | 126.25M | 130.18M | 193.66M | 165.68M | 2.60M | 213.00K | 171.00K | n/a | n/a |
Gross Profit | 326.17M | 209.49M | 150.62M | 179.84M | 103.04M | 114.74M | 25.88M | 1.50M | -171.00K | n/a | n/a |
Operating Income | 166.96M | -104.57M | -46.70M | -5.09M | -23.75M | -20.68M | -75.45M | -94.08M | -26.91M | -17.66M | -16.04M |
Interest Income | 15.62M | 1.05M | 12.00K | 232.00K | 1.94M | 1.69M | 582.00K | n/a | n/a | n/a | n/a |
Pretax Income | 75.73M | -28.85M | -3.37M | 27.58M | -22.72M | -39.13M | -74.86M | -94.18M | -27.25M | -17.92M | -16.20M |
Net Income | 48.16M | -25.00M | 71.52M | 26.75M | -8.15M | -39.13M | -74.86M | -94.18M | -27.25M | -17.92M | -16.20M |
Selling & General & Admin | 159.21M | 172.19M | 118.96M | 113.83M | 116.45M | 126.76M | 92.76M | 80.63M | 18.93M | 2.71M | 1.89M |
Research & Development | n/a | 3.98M | 9.45M | 9.77M | 10.34M | 8.66M | 8.57M | 14.95M | 7.97M | 14.96M | 14.16M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -94.00K | -348.00K | n/a | n/a |
Operating Expenses | 150.71M | 176.17M | 128.41M | 123.60M | 126.79M | 135.42M | 101.33M | 95.58M | 26.91M | 17.66M | 16.04M |
Interest Expense | 83.34M | 63.21M | 21.01M | 28.88M | 909.00K | 20.13M | 582.00K | 94.00K | 439.00K | 252.00K | 76.00K |
Selling & Marketing Expenses | 7.41M | 11.74M | 4.19M | 5.37M | 116.45M | 126.76M | 92.76M | 80.63M | n/a | n/a | n/a |
Cost & Expenses | 399.81M | 430.61M | 254.66M | 253.78M | 320.45M | 301.10M | 103.92M | 95.79M | 26.91M | 17.66M | 16.04M |
Income Tax | 27.58M | -3.85M | -74.89M | 830.00K | -14.57M | -110.91M | -1.16M | 94.00K | -91.00K | 252.00K | 79.00K |
Shares Outstanding (Basic) | 33.74M | 33.83M | 34.94M | 34.41M | 33.45M | 32.88M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
Shares Outstanding (Diluted) | 41.79M | 33.83M | 41.05M | 35.15M | 33.45M | 32.95M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
EPS (Basic) | 1.60 | -0.74 | 2.05 | 0.78 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.4 | -2.17 |
EPS (Diluted) | 1.29 | -0.74 | 1.86 | 0.76 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.4 | -2.17 |
EBITDA | 308.33M | 168.76M | 86.58M | 118.07M | -6.02M | 91.91M | -74.27M | -93.43M | -26.64M | -17.48M | -15.95M |
Depreciation & Amortization | 149.26M | 134.39M | 68.94M | 61.61M | 15.80M | 110.91M | 594.00K | 655.00K | 171.00K | 187.00K | 169.00K |